Evaluation of a synergistic drug combination with 177Lu-rhPSMA-10.1 for prostate cancer: Results of an in vitro screen and in vivo proof of concept study

lutetium lu-177 tezuvotide tetraxetan (177Lu-rhPSMA-10.1) - Bracco

Cotellic (cobimetinib) - Exelixis, Roche

C. Foxton 1; B. Cornelissen 2; E. O'Neill 2; B. Waldron 3; F. Pretzmann 4; R. Veggerby Grønlund 4; M. Wikke Hallund 4; D. J. Stevens3

Mar 6, 2024